ArticleNeuro-oncology advances
Impact of stereotactic radiosurgery timing relative to immune checkpoint blockade administration on brain metastasis disease and radionecrosis outcomes.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whether stereotactic radiosurgery (SRS) and immune checkpoint blockade (ICB) for brain metastases (BrM) have a time window for synergistic efficacy and toxicity is unclear. We examined this question in a large, contemporary cohort of patients who received concurrent SRS and ICB. Methods: Patients who received SRS for intact BrM within 1 month before to 6 months after an ICB cycle at a single center from 2018 to 2023 were included if they had no prior whole-brain radiotherapy or SRS to the same BrM. Intracranial progression-free survival (icPFS), local control (LC), distant brain control (DBC), overall survival (OS), and radionecrosis were analyzed by Kaplan-Meier and log-rank methods. Cox regression was used for uni/multivariable analysis (UVA/MVA). Results: A total of 419 BrM, 170 treatment episodes, and 134 patients were analyzed. In total, 43% and 40% of patients had melanoma and non-small cell lung cancer. A shorter SRS-ICB interval significantly correlated with improved icPFS, LC, and OS, but not DBC. This was true when analyzed as either a categorical or continuous factor. On MVA, SRS-ICB interval outperformed all factors including histology, ICB type, and de novo BrM status in predicting icPFS ( Conclusion: Delivering SRS closer to ICB cycles was associated with improved icPFS, LC, and OS without affecting radionecrosis rates. This may present a therapeutic opportunity to improve BrM outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.